title: Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
source: Yahoo
date: 2025-10-07
url: https://finnhub.io/api/news?id=63fd49c626ea81aff215ed2c020d329627033933faf029d1d850959a2fdd2956
Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint, with all once-daily icotrokinra dose groups achieving clinical responsea at Week 12 and showing clinically meaningful improvements versus placebo across key secondary endpo
